United Therapeutics / UTHR

About United Therapeutics

1110 Spring St., Silver Spring, Md. 20910
www.unither.com | 301-608-9292 | Founded: 1996

Industry: Biotechnology | Category: Public Companies

The founder of this biotech created the company to find a cure for her daughter's pulmonatry arterial hypertension. Its lead product, Remodulin, is designed to treat that disease. In December, United Therapeutics paid Eli Lilly $150 million for the rights to develop and market Tadalafil in the United States and Puerto Rico. The product, also for pulmonatry arterial hypertension, is under regulatory review. The company's other products treat cardiac arrhythmia, neuroblastoma and hepatitis C.

President and COO: Roger Jeffs

2008 Financial Data

Revenues: $281,497,000 | Net Income: $-42,789,000
Asssets: $871,319,000 | Earnings Per Share: $-1.87
Stockholder Equity: $507,699,000 | Annual Dividend: $0.00
Total employees: 363 | Local employees: 108